High efficacy of intensive immunochemotherapy for primary mediastinal B-cell lymphoma with prolonged follow up
J Romejko-Jarosinska, B Ostrowska… - Scientific Reports, 2022 - nature.com
Primary mediastinal B-cell lymphoma (PMBL) is currently curable in 85–95% of patients.
Treatment regimens frequently used include RCHOP±radiotherapy, DAEPOCH-R, or …
Treatment regimens frequently used include RCHOP±radiotherapy, DAEPOCH-R, or …
Matched control analysis suggests that R-CHOP followed by (R)-ICE may improve outcome in non-GCB DLBCL compared with R-CHOP
KS Bantilan, AN Smith, MJ Maurer… - Blood …, 2024 - ashpublications.org
Abstract Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)
is considered the standard-of-care for patients with advanced-stage diffuse large B-cell …
is considered the standard-of-care for patients with advanced-stage diffuse large B-cell …
Baseline and progressive adipopenia in newly diagnosed patients with diffuse large B-cell lymphoma with unfavorable features are associated with worse clinical …
M Lucijanic, R Huzjan Korunic, M Sedinic… - Leukemia & …, 2022 - Taylor & Francis
We retrospectively analyzed perirenal and subcutaneous fat thickness and their dynamics
from baseline to end-of-treatment computerized-tomography scans in a cohort of 118 newly …
from baseline to end-of-treatment computerized-tomography scans in a cohort of 118 newly …
Excellent survival after R‐Hyper‐CVAD in hospitalized patients with high‐risk large B‐cell lymphoma: The Karolinska experience
K Sonnevi, M Ljungqvist, JK Jóelsson, S Harrysson… - …, 2021 - Wiley Online Library
Patients with high‐risk aggressive B‐cell lymphoma exhibit poor survival after R‐CHOP.
More intensive regimens yield higher rates of remission but also of complication. We …
More intensive regimens yield higher rates of remission but also of complication. We …
Glomerular filtration rate is an independent prognostic factor in patients with B-large cell lymphoma
V Premužić, S Bašić-Kinda, I Radman, D Dujmović… - Medicine, 2023 - journals.lww.com
Chronic kidney dysfunction is associated with increased mortality in multiple cancer types.
Preliminary evidence suggests the same to be true for B-large cell lymphomas (B-LCL). To …
Preliminary evidence suggests the same to be true for B-large cell lymphomas (B-LCL). To …
No Evident Prognostic Benefit of Statin Use in Diffuse Large B-Cell Lymphoma Patients with Unfavorable Disease Features Treated with R-DA-EPOCH
Recent reports indicate that patients with aggressive non-Hodgkin lymphomas might benefit
if concomitantly receiving statins with rituximab, cyclophosphamide, hydroxydaunorubicin …
if concomitantly receiving statins with rituximab, cyclophosphamide, hydroxydaunorubicin …
Izraženost i klinički značaj galektina-3, VEGF-a i NF-κB u difuznom B-velikostaničnom limfomu
S Bašić-Kinda - 2023 - repozitorij.mef.unizg.hr
Uvod i svrha rada: Galektin-3 je jedini galektin kimerične strukture. Uključen je u važne
stanične procese: regulaciju proliferacije stanica, apoptozu i angiogenezu. Više od 50 …
stanične procese: regulaciju proliferacije stanica, apoptozu i angiogenezu. Više od 50 …
Dose adjusted R-EPOCH and other etoposide-containing regimens in first-line treatment of diffuse large B-cell lymphoma
I Aurer - Acta Haematologica Polonica, 2021 - journals.viamedica.pl
Etoposide is a well-known cytotoxic agent effective in the treatment of B-large cell lymphoma
(B-LCL). Currently, there is no consensus regarding the place of etoposide-containing …
(B-LCL). Currently, there is no consensus regarding the place of etoposide-containing …
Infuzijski protokol DA-R-EPOCH za liječenje B-velikostaničnog limfoma u starijih bolesnika
N Živković - 2021 - repozitorij.unizg.hr
Sažetak UVOD: B-velikostanični limfom (B-LCL) je najčešći tip agresivnog ne-Hodgkinovog
limfoma. Prognoza starijih pacijenata s visokorizičnim B-LCLom je nezadovoljavajuća. Mladi …
limfoma. Prognoza starijih pacijenata s visokorizičnim B-LCLom je nezadovoljavajuća. Mladi …